Company profile for Palvella Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Palvella is a biopharmaceutical company committed to serving patients with debilitating rare, genetic diseases through the development and commercialization of life-changing, pathogenetically targeted therapies. The company was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. The Palvella t...
Palvella is a biopharmaceutical company committed to serving patients with debilitating rare, genetic diseases through the development and commercialization of life-changing, pathogenetically targeted therapies. The company was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. The Palvella team is committed to recruiting passionate and like-minded collaborators to ensure we expeditiously deliver on this important mission for rare disease patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
125 Strafford Avenue Suite #360 Wayne, PA 19087
Telephone
Telephone
484-253-1460
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/11/3185323/0/en/Palvella-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181193/0/en/Palvella-Therapeutics-Announces-New-QTORIN-Product-Candidate-QTORIN-Pitavastatin-for-the-Treatment-of-Disseminated-Superficial-Actinic-Porokeratosis-DSAP-a-Rare-Chronic-and-Pre-Can.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180202/0/en/Palvella-Therapeutics-to-Host-Third-Quarter-2025-Financial-Results-and-Corporate-Update-Conference-Call-on-November-11-2025.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/13/3165451/0/en/U-S-Food-and-Drug-Administration-Awards-Year-Two-Proceeds-from-Orphan-Products-Grant-Supporting-Palvella-Therapeutics-Phase-3-SELVA-Trial-of-QTORIN-Rapamycin-for-Microcystic-Lympha.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/09/24/3155284/0/en/Palvella-Therapeutics-Announces-Expansion-of-QTORIN-Rapamycin-s-Development-into-Clinically-Significant-Angiokeratomas-a-Rare-Chronically-Debilitating-Lymphatic-Disease-with-No-FDA.html

GLOBENEWSWIRE
24 Sep 2025

https://www.globenewswire.com/news-release/2025/09/17/3151540/0/en/Palvella-Therapeutics-Announces-Scientific-Publication-in-Lymphatic-Research-and-Biology-Highlighting-Recent-Advances-in-the-Pathogenesis-of-Venous-Malformations-and-the-Real-World.html

GLOBENEWSWIRE
17 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty